The United States Patent and Trademark Office has issued U.S. Patent No. 12,648,970, “Compositions and Methods of Treatment Comprising Tumor-Targeting Bacteria and Chemotherapy or Immunotherapy Agent”. Congratulations to the team.
The patented technology underpins the lab’s engineered bacterial therapeutics program, which uses tumor-colonizing bacteria to deliver immunomodulatory payloads directly into the tumor microenvironment. That program is described on the Research page.